NZ600840A - Indole compound and pharmaceutical use thereof - Google Patents

Indole compound and pharmaceutical use thereof

Info

Publication number
NZ600840A
NZ600840A NZ600840A NZ60084010A NZ600840A NZ 600840 A NZ600840 A NZ 600840A NZ 600840 A NZ600840 A NZ 600840A NZ 60084010 A NZ60084010 A NZ 60084010A NZ 600840 A NZ600840 A NZ 600840A
Authority
NZ
New Zealand
Prior art keywords
formula
indazol
indol
benzimidazole
tetrahydro
Prior art date
Application number
NZ600840A
Other languages
English (en)
Inventor
Michihide Maekawa
Shinichi Kikuchi
Teruhiko Inoue
Tetsudo Kaya
Motoya Suzuki
Koji Matsumura
Ritsuki Masuo
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NZ600840A publication Critical patent/NZ600840A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ600840A 2009-11-25 2010-11-25 Indole compound and pharmaceutical use thereof NZ600840A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009268040 2009-11-25
PCT/JP2010/070988 WO2011065402A1 (ja) 2009-11-25 2010-11-25 インドール化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
NZ600840A true NZ600840A (en) 2014-01-31

Family

ID=44066507

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ600840A NZ600840A (en) 2009-11-25 2010-11-25 Indole compound and pharmaceutical use thereof

Country Status (31)

Country Link
US (6) US8299070B2 (cg-RX-API-DMAC7.html)
EP (3) EP2505586B1 (cg-RX-API-DMAC7.html)
JP (6) JP5734628B2 (cg-RX-API-DMAC7.html)
KR (1) KR101766502B1 (cg-RX-API-DMAC7.html)
CN (1) CN102712624B (cg-RX-API-DMAC7.html)
AR (1) AR079164A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010323579C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012012529B1 (cg-RX-API-DMAC7.html)
CA (1) CA2781660C (cg-RX-API-DMAC7.html)
CL (1) CL2012001328A1 (cg-RX-API-DMAC7.html)
CO (1) CO6541645A2 (cg-RX-API-DMAC7.html)
CY (1) CY1117559T1 (cg-RX-API-DMAC7.html)
DK (1) DK2505586T3 (cg-RX-API-DMAC7.html)
ES (1) ES2572935T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160579T1 (cg-RX-API-DMAC7.html)
HU (1) HUE028016T2 (cg-RX-API-DMAC7.html)
IL (1) IL220009A (cg-RX-API-DMAC7.html)
ME (1) ME02447B (cg-RX-API-DMAC7.html)
MX (1) MX2012006017A (cg-RX-API-DMAC7.html)
MY (1) MY161095A (cg-RX-API-DMAC7.html)
NZ (1) NZ600840A (cg-RX-API-DMAC7.html)
PE (1) PE20121358A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012501021A1 (cg-RX-API-DMAC7.html)
PL (1) PL2505586T3 (cg-RX-API-DMAC7.html)
PT (1) PT2505586E (cg-RX-API-DMAC7.html)
RS (1) RS54910B1 (cg-RX-API-DMAC7.html)
RU (1) RU2556216C2 (cg-RX-API-DMAC7.html)
SI (1) SI2505586T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600258B (cg-RX-API-DMAC7.html)
TW (1) TWI491591B (cg-RX-API-DMAC7.html)
WO (1) WO2011065402A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
CA2890111A1 (en) 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
CN103804364A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103800337A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804361A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804291A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804351A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804363A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804302A (zh) * 2012-11-14 2014-05-21 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103804272A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
AR099936A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
ES2748324T3 (es) * 2014-07-04 2020-03-16 Japan Tobacco Inc Método para producir un compuesto de indol
WO2016010108A1 (ja) * 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
CN104356086A (zh) * 2014-11-28 2015-02-18 湖南科技大学 一种适于工业生产3-吗啉酮的制备方法
CN112118843B (zh) * 2018-05-25 2023-09-29 日本烟草产业株式会社 使用吲哚化合物治疗疼痛或间质性膀胱炎的方法
JP7322007B2 (ja) * 2018-05-25 2023-08-07 日本たばこ産業株式会社 インドール化合物を含むネフローゼ症候群の治療又は予防剤
JP7407705B2 (ja) * 2018-05-25 2024-01-04 日本たばこ産業株式会社 インドール化合物を含む多発性硬化症の治療又は予防剤
IL293831B2 (en) 2019-12-20 2024-02-01 Pfizer Benzimidazole derivatives
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
US20240132477A1 (en) * 2020-12-15 2024-04-25 Pfizer Inc. Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease
US20240124439A1 (en) * 2020-12-15 2024-04-18 Pfizer Inc. Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease
US20240279202A1 (en) * 2021-05-03 2024-08-22 Nurix Therapeutics, Inc. Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their use
CA3217892A1 (en) * 2021-05-03 2022-11-10 Joel Mcintosh Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
TW202315618A (zh) * 2021-06-11 2023-04-16 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物
AU2022370351A1 (en) * 2021-10-19 2024-05-02 Nurix Therapeutics, Inc. Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
KR20250166329A (ko) * 2023-04-13 2025-11-27 다나틀라스 파마슈티컬즈 씨오., 엘티디. 티아디아졸론 유도체 및 이의 조성물과 응용

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US953411A (en) * 1908-09-02 1910-03-29 Erastus De Moulin Trick weight-lifting machine.
BR0213562A (pt) * 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
DK1474425T3 (da) * 2002-01-07 2006-09-25 Eisai Co Ltd Deazapuriner og anvendelser deraf
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2005026175A1 (en) * 2003-09-08 2005-03-24 Aventis Pharmaceuticals Inc. Thienopyrazoles
EP1880993A4 (en) * 2005-04-19 2009-12-30 Kyowa Hakko Kirin Co Ltd NITROGENIC HETEROCYCLIC COMPOUND
EP1968580A2 (en) 2005-12-20 2008-09-17 Boehringer Ingelheim International Gmbh 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders
GB0602178D0 (en) * 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
MX2008012482A (es) * 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
AU2007254179B2 (en) * 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
EP2108642A1 (en) * 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
EP2081892A4 (en) 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP2009268040A (ja) 2008-04-23 2009-11-12 Teruhiko Daiho ループアンテナ装置
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof

Also Published As

Publication number Publication date
CA2781660C (en) 2018-06-26
PE20121358A1 (es) 2012-10-23
ME02447B (me) 2016-09-20
US20130116240A1 (en) 2013-05-09
ES2572935T3 (es) 2016-06-03
JP2021091718A (ja) 2021-06-17
CN102712624A (zh) 2012-10-03
IL220009A0 (en) 2012-07-31
CO6541645A2 (es) 2012-10-16
HUE028016T2 (en) 2016-11-28
SMT201600258B (it) 2016-08-31
TW201124378A (en) 2011-07-16
JP2015172051A (ja) 2015-10-01
CY1117559T1 (el) 2017-04-26
AR079164A1 (es) 2011-12-28
US20180362506A1 (en) 2018-12-20
JP5734628B2 (ja) 2015-06-17
AU2010323579C1 (en) 2016-11-03
DK2505586T3 (en) 2016-05-30
PH12012501021A1 (en) 2013-01-14
CA2781660A1 (en) 2011-06-03
JP2017039761A (ja) 2017-02-23
KR101766502B1 (ko) 2017-08-08
EP3059234A1 (en) 2016-08-24
CL2012001328A1 (es) 2012-10-05
BR112012012529B1 (pt) 2021-10-26
RS54910B1 (sr) 2016-10-31
EP3766877A1 (en) 2021-01-20
MY161095A (en) 2017-04-14
RU2556216C2 (ru) 2015-07-10
KR20120096540A (ko) 2012-08-30
MX2012006017A (es) 2012-06-25
JP2011132222A (ja) 2011-07-07
AU2010323579A1 (en) 2012-07-19
PT2505586E (pt) 2016-06-03
BR112012012529A2 (pt) 2016-05-03
EP2505586A4 (en) 2013-05-15
JP2018158935A (ja) 2018-10-11
PL2505586T3 (pl) 2016-12-30
EP2505586A1 (en) 2012-10-03
TWI491591B (zh) 2015-07-11
US20170267662A1 (en) 2017-09-21
US20110306599A1 (en) 2011-12-15
AU2010323579B2 (en) 2016-05-19
HRP20160579T1 (hr) 2016-07-29
EP2505586B1 (en) 2016-03-02
SI2505586T1 (sl) 2016-08-31
CN102712624B (zh) 2014-06-04
US8299070B2 (en) 2012-10-30
US20210284627A1 (en) 2021-09-16
HK1174025A1 (en) 2013-05-31
WO2011065402A1 (ja) 2011-06-03
RU2012126129A (ru) 2013-12-27
JP2020079276A (ja) 2020-05-28
US20200255408A1 (en) 2020-08-13
IL220009A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
NZ600840A (en) Indole compound and pharmaceutical use thereof
MX2011013771A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17.
MY162940A (en) Quinoline derivative-containing pharmaceutical composition
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
IN2012DN02551A (cg-RX-API-DMAC7.html)
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
NZ588121A (en) Novel estrogen receptor ligands
WO2007087204A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
MY148703A (en) Polycyclic cinnamide derivatives
IN2012DN02556A (cg-RX-API-DMAC7.html)
MY150507A (en) Polycyclic compound
EA200870336A1 (ru) Полициклические производные циннамида
LTPA2014015I1 (lt) Glikopirolato ir beta2 adrenoceptoriaus agonisto derinys
UA115320C2 (uk) Інгібітори кінази
MX2011012264A (es) Derivados spiro[2.4]heptano puenteados como agonistas del receptor de lipoxina a(alx) y/o de formil peptido tipo 2 (fprl2).
MX2009003939A (es) Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes.
TW200638933A (en) Compounds for inflammation and immune-related uses
MX2010004232A (es) Compuesto de indolina de pirimidilo.
MX344109B (es) Formulaciones de sal de meglumina del ácido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxílico.
WO2009013348A3 (en) Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
WO2008045777A3 (en) A process for the preparation of benzimidazole derivatives and their salts
IN2012DN02502A (cg-RX-API-DMAC7.html)
PH12014502210A1 (en) Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 NOV 2017 BY CPA GLOBAL

Effective date: 20140911

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2018 BY CPA GLOBAL

Effective date: 20171012

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2019 BY CPA GLOBAL

Effective date: 20181011

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2020 BY CPA GLOBAL

Effective date: 20191010

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2021 BY CPA GLOBAL

Effective date: 20201008

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2022 BY CPA GLOBAL

Effective date: 20211014

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2023 BY CPA GLOBAL

Effective date: 20221015

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2024 BY CPA GLOBAL

Effective date: 20231013

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241011

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 NOV 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251010